Alignment healthcare exec sells shares worth over $174,000

Published 16/08/2024, 22:02
Alignment healthcare exec sells shares worth over $174,000

In a recent transaction, Dawn Christine Maroney, President of Markets at Alignment Healthcare, Inc. (NASDAQ:ALHC), sold 20,000 shares of the company's common stock. The sale, recorded on August 15, 2024, amounted to over $174,000, with shares sold at a weighted-average price of $8.701.

The transactions were carried out in multiple sales, with prices ranging from $8.59 to $8.81 per share, according to the footnotes of the filing. Following the sale, Maroney's direct ownership in the company stands at 1,796,097 shares.

The sale was reported in a Form 4 filing with the Securities and Exchange Commission, which was signed by Christopher J. Joyce, as Attorney-in-Fact, for Dawn C. Maroney, and dated August 16, 2024.

Investors and security holders of Alignment Healthcare, Inc. have been assured by Maroney that full information regarding the number of shares sold at each specific price within the range will be provided upon request.

This sale by a high-ranking executive at Alignment Healthcare provides market watchers with insights into insider activity, which can be an indicator of the company's financial health and future prospects. However, it is important to note that insider transactions may be based on individual financial planning and not necessarily on the company's performance.

In other recent news, Alignment Healthcare has undergone significant changes to its board structure and entered a new consulting agreement with former board member Jeffrey Margolis. This follows the immediate resignations of Margolis and Thomas Carella, who served on the board for ten and seven years respectively. Their departures were not due to any disagreements regarding operations, policies, or practices. Margolis will now serve in a consulting capacity until June 30, 2026, with an initial payment of $18,333, followed by varying monthly retainers.

In terms of financial performance, Alignment Healthcare displayed impressive growth in the second quarter, with a 56% increase in health plan membership and a 47% surge in revenue year-over-year. This led to an upward adjustment in year-end membership expectations by 8,000 members and a forecast of at least 20% growth in 2025.

In response to these results, Baird, TD Cowen, and Piper Sandler all raised their stock price targets for the company. Baird, specifically, raised its target from $10.00 to $11.00, highlighting the company's potential for strong performance in 2025 due to key factors such as a projected improvement in the medical loss ratio and a Star Ratings advantage in California. These are the recent developments shaping Alignment Healthcare's trajectory.

InvestingPro Insights

As investors digest the recent insider transaction at Alignment Healthcare, Inc. (NASDAQ:ALHC), it's crucial to consider the company's financial metrics and market performance to gain a comprehensive view. According to InvestingPro data, Alignment Healthcare has a market capitalization of $1.65 billion and has experienced significant revenue growth over the last twelve months as of Q2 2024, with a 37.46% increase. This growth is further highlighted by a quarterly revenue growth of 47.34% in Q2 2024.

Despite this revenue growth, the company faces challenges as reflected in its gross profit margin of 10.65%, which points to potential inefficiencies that could be impacting profitability. Furthermore, analysts have revised their earnings downwards for the upcoming period, and they do not anticipate the company will be profitable this year. This aligns with the current negative Price/Earnings (P/E) ratio of -10.66, which suggests that investors are not expecting immediate earnings growth.

On the upside, Alignment Healthcare's stock has demonstrated resilience with a strong return over the last three months, posting a 22.89% price total return. This positive momentum is also seen over the last six months, with a 29.37% price total return. However, it's worth noting that the stock is trading at a high Price/Book multiple of 13.45, which may raise concerns about valuation among some investors.

For those looking to delve deeper into Alignment Healthcare's financials and future outlook, InvestingPro offers additional InvestingPro Tips, which can be accessed at https://www.investing.com/pro/ALHC. There are currently 9 additional tips available on InvestingPro that can provide further insights into the company's performance and investment potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.